Serum netrin-1 level and insulin resistance in type 2 diabetes mellitus
Abstract
Background & objective: Netrin-1 is commonly recognized as a neural guidance cue that has been suggested to play a role in pancreas development. Multiple studies have reported on the regenerative, angiogenic, and anti-inflammatory properties of netrin-1 in various tissues. In hyperglycemia, netrin-1 may support insulin secretion and reduce inflammation. This study was aimed to investigate the correlation of serum Netrin-1 with Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).
Methodology: This study comprised a total of 81 patients diagnosed with type 2 diabetes mellitus (T2DM) and 79 apparently healthy individual as controls. For each participant' following an overnight fasting, samples of blood were taken. Biochemical parameters were estimated including glycated hemoglobin, fasting blood glucose, serum insulin, and serum netrin-1 levels.
Result: This study revealed that T2DM patients had significantly higher serum netrin-1 levels than the control group. There was a significant positive correlation between netrin-1 and HOMA-IR.
Conclusion: The mean serum concentration of netrin-1 was significantly higher in type 2 diabetes mellitus patients than in healthy individuals. There is a positive correlation between insulin resistance and netrin-1 in type 2 diabetes mellitus. Further studies involving larger sample sizes are needed to clarify the real relationship and to improve reliability and replicability and to provide an insight to the pathogenesis, diagnosis, prevention, and treatment of type 2 diabetes mellitus.
Abbreviations: ADA - American Diabetes Association DCC - Deleted Receptors in Colorectal Cancer; HOMA-IR - Homeostatic Model Assessment of Insulin Resistance; T2DM - Type 2 Diabetes Mellitus; UNC5 - Uncoordinated 5;
Keywords: Diabetes Mellitus; Hyperglycemia; Insulin Resistance; Netrin-1
Citation: Al-Shakour AA, Khalid HA, Naser NA. Serum netrin-1 level and insulin resistance in type 2 diabetes mellitus. Anaesth. pain intensive care 2024;28(2):341−346; DOI: 10.35975/apic.v28i2.2422
Received: January 07, 2024; Revised: February 01, 2024; Accepted: February 08, 2024
